Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

Program Overview

The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagganath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.

Credit Expired

Target Audience

Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses

Educational Objectives

Upon completion of this activity, participants should be better able to:

Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM

Activity Faculty

Sundar Jagannath, MD, FASCO

Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY

James Hoffman, MD

Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL

María-Victoria Mateos, MD, PhD

Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain

Featured RMEI CE Activities – Earn CE Credit(s)

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Sundar Jagannath, MD, FASCO

James Hoffman, MD

María-Victoria Mateos, MD, PhD

Case Challenges in Hereditary Angioedema: Innovative Therapeutic Strategies for a Normal Life: A Care Team Forum®

A Balancing Act: Safety and Success in CMV Management for HCT Patients: A Clinical Forum®

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

Subscribe